Homepage
Latest Videos
Latest Videos
Brightcove Home Latest Listing
Breast Cancer
Breast Cancer
Brightcove Cards Listing
Prostate Cancer
Brightcove Cards Listing
Multiple Myeloma
Multiple Myeloma
Brightcove Cards Listing
Popular on MedEnrich
Popular in No name
Breast Cancer3m 36s
Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer
Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
tumor-infiltrating lymphocytes (tils)
promising biomarker
1
Tumor Infiltrating Lymphocytes as Predictive...
Breast Cancer29m 30s
SABCS Update 2022
Summary of Key Abstracts from SABCS 2022
recurrence score
tailor-x
destiny breast 03
adjuvant cdk4/6 inhibitor
antibody drug conjugates
1
SABCS Update 2022
Multiple Myeloma4m 12s
Key Practice Points -Myeloma Related Renal Impairment
In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
myeloma
renal impairment
key practice points
1
Key Practice Points -Myeloma Related Renal...
Prostate Cancer11m 38s
Treatment Intensification in Metastatic Castration Sensitive Prostate Cancer
PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.
treatment intensification
mhspc
triplet therapy
peace-1 clinical trial
1
Treatment Intensification in Metastatic Castration...
Multiple Myeloma10m 40s
Recommendations -Management of Myeloma Related Renal Impairment
Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.
myeloma
renal impairment
lancet guidelines
1
Recommendations -Management of Myeloma Related...
Breast Cancer8m 55s
Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy
Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
trastuzumab-deruxtecan (t-dxd)
her2 low breast cancers
1
Understanding HER-2 Low Breast Cancer Entity &...
Oncology1m 36s
Enhancing Global Access to Cancer Medicines
Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease.
biosimilars
access
generics
1
Enhancing Global Access to Cancer Medicines
Multiple Myeloma7m 42s
MRD Assesment in Multiple Myeloma -Ready for Prime Time
Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
minimum residual disease (mrd)
mrd negativity
multiple myeloma
1
MRD Assesment in Multiple Myeloma -Ready for Prime...
Myelodysplastic Syndromes3m 14s
Low Risk MDS - Key Practice Points
Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
ipss -m
low risk
molecular features
1
Low Risk MDS - Key Practice Points
Oncology13m 52s
Guidelines for Treatment of Diffuse Gliomas
Classification & treatment of Gliomas have evolved from erstwhile histopathology based to recent one incorporating molecular markers.
glioma
guidelines
idh mutations
1
Guidelines for Treatment of Diffuse Gliomas
For Pharmacist
For Pharmacist
Brightcove Cards Listing
Webinars
Webinar Cards Listing
MedBytes
MedBytes
Medbytes Cards Listing
Login
To get access to full MedEnrich experience, please Sign in
Don’t have an account? Register Now